Table 1.
Clinicopathological characteristics for patients within the population-based patient cohort applied for IHC assessment compared to the primary investigation cohort and the validation cohort (TCGA).
| Variable | Cohorts, n (%) | ||||
|---|---|---|---|---|---|
| Population based (n = 444)a | Primary investigation (n = 79)b | P valuec | Validation (TCGA) (n = 304)c | P valued | |
| Age at diagnosis (median) | 0.14 | 0.03 | |||
| <44 | 213 (48) | 45 (57) | 121 (39) | ||
| ≥44 | 231 (52) | 34 (43) | 183 (60) | ||
| FIGO-09 stage | 0.03 | <0.001 | |||
| I | 322 (73) | 67 (84) | 161 (54) | ||
| II–IV | 122 (27) | 13 (16) | 136 (46) | ||
| Histologic subtype | 0.17 | <0.001 | |||
| SCC | 318 (72) | 49 (61) | 253 (83) | ||
| AC | 91 (20) | 22 (28) | 45 (15) | ||
| Other histology | 35 (8) | 9 (11) | 6 (2) | ||
| Metastatic lymph node | 0.28 | ||||
| No | 250 (69) | 57 (79) | |||
| Yes | 46 (31) | 15 (21) | |||
IHC immunohistochemistry, FIGO The Féderation Internationale de Gynécologie et d’Obstétrique, TCGA The Cancer Genome Atlas, SCC squamous cell carcinoma, AC adenocarcinoma.
Statistically significant p < 0.05 values are in bold.
aMissing data in population-based cohort: metastatic lymph node = 148.
bMissing data primary investigation cohort: age, n = 1 and metastatic lymph node, n = 8.
cMissing data in validation (TCGA) cohort: FIGO, n = 7. Metastatic lymph node status was not available.
dPearson’s χ2 test.